Not provided
Not provided
Not provided
Not provided
Not provided
FDA changed classification of device and no longer requires this type of clinical data
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Evaluate the diagnostic accuracy of the Planmed Sophie Nuance Full Field Digital Mammography (FFDM) X-ray System compared to screen-film mammography (SFM) in the detection of breast cancer.
Objectives: 1) To establish the non-inferiority of the diagnostic accuracy of the Planmed Sophie Nuance Full Field Digital Mammography (FFDM) X-ray System compared to screen-film mammography (SFM) in the detection of breast cancer; and 2) To demonstrate in a comparative side-by-side feature analysis that interpretations based on the Planmed Sophie Nuance FFDM X-ray System are diagnostically non-inferior to SFM in the detection of breast cancer.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| mammography | Experimental | Women must be at least 40 years of age, presenting for routine breast cancer screening or presenting with one or both breasts scored 4 or 5 on the BI-RADS scale as a result of SFM either for routine breast cancer screening or for follow-up or diagnostic mammography |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Full Field Digital Mammogram (Planmed Sophie Nuance) | Device | Full Field Digital Mammogram |
|
| Measure | Description | Time Frame |
|---|---|---|
| Area under ROC curve based on subjects' maximum POM scores; sensitivity based on subjects' maximum BI-RADS scores with 4 or higher as positive for cancer; and specificity based on subjects maximum BI-RADS scores with 4 or higher as positive for cancer | Approximately one year after completion of study. |
| Measure | Description | Time Frame |
|---|---|---|
| area under the ROC curve based on the maximum POM score per subject-breast | Approximately one year after completion of study. | |
| area under the ROC curve based on the POM scores from the ten regions of a subject's breasts; | Approximately one year after completion of study. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Subject is pregnant or possibly pregnant or planning pregnancy within the next 15 months
Subject has undergone a breast augmentation or breast implant? Has subject had any of the following breast procedures?
Fine needle or cyst aspiration NOT Eligible if within past year Biopsy Not Eligible if within past year Lumpectomy (for breast cancer) Mastectomy (for breast cancer) Radiation therapy Breast reconstruction Breast reduction Not Eligible if within past year
Subject has had an invasive breast procedure or operation within the past year
Subject has significant existing breast trauma
Subject has a history of breast cancer treated with operation or radiation
Subject has any other condition or personal circumstance that, in the judgment of the investigator, might interfere with the collection of complete good quality data
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Sami Tohka, PhD | Planmed Oy | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Mroz-Baier Breast Care Clinic | Memphis | Tennessee | 38119 | United States | ||
| The Rose |
Not provided
| ID | Term |
|---|---|
| D001943 | Breast Neoplasms |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D001941 | Breast Diseases |
| D012871 | Skin Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D008327 | Mammography |
| ID | Term |
|---|---|
| D011859 | Radiography |
| D003952 | Diagnostic Imaging |
| D019937 | Diagnostic Techniques and Procedures |
| D003933 | Diagnosis |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| sensitivity based on subjects' maximum BI-RADS scores using a cut-point of 3 or higher as positive for cancer; | Approximately one year after completion of study. |
| specificity based on subjects' maximum BI-RADS scores using a cut-point of 3 or higher as positive for cancer; | Approximately one year after completion of study. |
| Sensitivity and specificity based on the maximum BI-RADS scores per subject-breast using 4 or higher for positive; and sensitivity and specificity based on the maximum BI-RADS scores per subject-breast using 3 or higher for positive. | Approximately one year after completion of study. |
| Feature Analysis Study; side by side assessment of SFM and FFDM images and comparison of quality features: lesion conspicuity, tissue visibility at chest wall, tissue visibility at skin line, axillary details (MLO), overall contrast, overall sharpness | Approximately one year after completion of study. |
| Adverse event assessment | Approximately 24 hours after completion of FFDM |
| Houston |
| Texas |
| 77034 |
| United States |
| D017437 |
| Skin and Connective Tissue Diseases |